Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HER2-directed Biosimilar OgivriTM in Breast Cancer: Real World Observational Trial for the Description of Quality of Life and Outcome Using ePRO (OGIPRO- Trial)

NCT05234021 is registered in ClinicalTrials.gov with OnkoZentrum Zürich AG as lead sponsor.

NCT NCT05234021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05234021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HER2-directed Biosimilar OgivriTM in Breast Cancer: Real World Observational Trial for the Description of Quality of Life and Outcome Using ePRO (OGIPRO- Trial)
Lead sponsor
OnkoZentrum Zürich AG
Phase
Observational
Overall status
Completed
Start date
December 14, 2021
Completion date
June 30, 2023
Enrollment
52 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

biosimilar, her2-positive breast cancer, patient reported outcome